“Fundamentally applied” is the name of our video series with researchers from the Institut Pasteur, whose research work has led to imagining new healthcare products, currently in development.
In this new episode, Caroline Demangel, Head of Immunobiology and Therapy Unit at Institut Pasteur, tells how the study of a toxin from a mycobacterium responsible for a tropical disease called Buruli ulcer, led to the identification of a potential new therapeutic target for the treatment of multiple myeloma.
This adventure led her to collaborate with Argobio, a startup studio, which was a decisive factor in the project.
To watch her testimony:
